Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

A at week 20 of post-treatment follow-up. Of the remaining 8 patients enrolled in Arm D, 4 discontinued due to adverse events prior to week 12, and 4 did not achieve RVR.

Interim 12-Week Safety Analysis of PROVE 1

In PROVE 1, the types of adverse events that have been commonly observed with interferon and ribavirin were seen across all treatment arms. The most common adverse events, regardless of treatment assignment, were fatigue, rash, headache and nausea. Gastrointestinal disorders, rash and anemia were more common in the telaprevir arms.

In the telaprevir dosing arms, the incidence of treatment discontinuations due to adverse events through 12 weeks was 11% (19 of 175 patients), compared to 3% (2 of 75 patients) in the control arm. The difference between the two groups is due to the greater number of discontinuations due to rash, gastrointestinal disorders and anemia in the telaprevir arms compared to the control arm. The most common reason for treatment discontinuation in the telaprevir arms was rash (7 patients), and the median time to discontinuation in these patients was 64 days.

Webcast of Investor Presentation

Vertex intends to provide a live webcast of its investor presentation from Barcelona beginning at 7:30 p.m. CEST (1:30 p.m. EDT) on Saturday, April 14. The presentation may be accessed from the 'Events Calendar' on the homepage of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website until April 27, 2007. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Telaprevir (VX-950)

Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an enzyme essential for viral replication, and is one of the most advanced investigational agents in development that specifically targets HCV. Vertex is conducting a global Phase 2b clinical development program for telaprevir consis
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:10/22/2014)... , Oct. 22, 2014 Sanomedics International ... 2014 report by Global Research & Data Services, demand ... year from 2014 through 2018, as demand for more ... is the world,s largest market for thermometers, ... advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... and AUSTIN, Texas , ... PureMHC LLC today announced they have entered into ... antibody-based immunotherapies designed to target cancers. ... peptides displayed on the surfaces of tumor cells ... targets (PTTs), derived from proteins that play a ...
(Date:10/22/2014)... 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... IAP310 study have been published in Regional ... journal with broad, multidisciplinary readership. IAP310 was a ... and efficacy of Zalviso, also referred to as ... treatment of post-operative pain in patients following open ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
... InfoLogix, Inc. (Pink Sheets: IFLG ), ... the healthcare and commercial industries, announced today that it ... Faire and Regional Conference, sponsored by HIMSS South Florida ... Grand Hotel in Davies, FL (situated North of Miami) ...
... Mass., Oct. 25 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), ... and development, focusing on the early diagnosis and preventive ... it has been selected by Windhover as one of ... the cardiovascular/metabolic category. This announcement is part of the ...
Cached Medicine Technology:InfoLogix to Present at South Florida Healthcare Trade Faire & Regional Conference 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 3
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... in Dallas. But, mental health specialists say overblown fear is ... Obama on Friday appointed an Ebola "czar" to oversee the ... nurses who cared for a Liberian man who died of ... the U.S. cases are miniscule in the context of the ...
(Date:10/22/2014)... Angeles, California (PRWEB) October 22, 2014 Hay ... 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) ... field of Yoga & Recovery. This book is meant ... thrive in a life of recovery. , Recovery 2.0 ... the 12 Steps; Recovery 2.0 is a guide for what ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Two sisters in ... heart damage. Ilina and Medha Krishen use electronic ... sounds of trouble in breathing patterns or heartbeats. ... in Michigan, wanted to find a way to detect ... pollutants. Using an electronic stethoscope, Ilina recorded one breath ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... Accounting Related to Two Transactions , PHOENIX, Feb. 23 ... in stabilized rice bran (SRB) nutrient research and technology, ... recommendations of the Audit Committee of its Board of ... fiscal year ended December 31, 2007. This includes the ...
... Remember events to be held Feb. 27 - March 1 ... Feb. 23 FamilyLife, the global, donor-supported leader in marriage ... on Feb. 27 - March 1 and again March 20 ... conference aims to strengthen healthy marriages and heal troubled ones ...
... Feb. 23 Milestone Scientific Inc. (OTC Bulletin Board: ... announced that it will be exhibiting at the upcoming ... In light of its highly successful sales of the ... at last year,s CDS conference, coupled with four successive ...
... offers diabetes education, healthy food-sampling and a special performance ... History Month comes to a close, Grammy-nominated singer-songwriter Angie ... C onnected and E mpowered (F.A.C.E.) Diabetes ... Birmingham on February 28 to help empower and inspire ...
... 23 /PRNewswire/ -- DataMentors(R), the industry ... company, today announced the release of its much ... integrates data from multiple platforms. DataFuse is used ... mid-size and "Fortune 500" companies, providing the industry,s ...
... Drinks and Activia Fiber Bring Great Taste and Digestive ... The Dannon Company, Inc., announced today that it ... products to its probiotic portfolio. Both cultured fresh dairy ... Bifidus Regularis(TM), have the same scientifically proven benefits of ...
Cached Medicine News:Health News:NutraCea to Restate Financial Statements for 2007 and 2008 2Health News:NutraCea to Restate Financial Statements for 2007 and 2008 3Health News:NutraCea to Restate Financial Statements for 2007 and 2008 4Health News:NutraCea to Restate Financial Statements for 2007 and 2008 5Health News:FamilyLife Offers Economic Relief and Hope for Baltimore Marriages by Inviting Recently Unemployed Couples to Attend Marriage Conference for Free 2Health News:FamilyLife Offers Economic Relief and Hope for Baltimore Marriages by Inviting Recently Unemployed Couples to Attend Marriage Conference for Free 3Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 2Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 3Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 4Health News:Grammy-nominated Singer Angie Stone Encourages African-Americans in Birmingham to Fearlessly FACE Diabetes 2Health News:Grammy-nominated Singer Angie Stone Encourages African-Americans in Birmingham to Fearlessly FACE Diabetes 3Health News:Grammy-nominated Singer Angie Stone Encourages African-Americans in Birmingham to Fearlessly FACE Diabetes 4Health News:Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed 2Health News:Dannon(TM) Expands Probiotic Portfolio with New Activia(TM) Extensions 2Health News:Dannon(TM) Expands Probiotic Portfolio with New Activia(TM) Extensions 3
... The Autocorr Pulse Oximeter with SAC (Serial ... patented software to extract SpO 2 , ... a new way. This cost-effective compact ... functions as standard features, and a data ...
... The Autocorr Plus, the fourth in ... versatile pulse oximeter/ECG/Respiration Monitor, with 3 ... digital oximetry with SAC (Serial Autocorrelation) ... electroluminescent screen display provides two user ...
... Oximeter is a cost-effective, stand-alone monitor that ... rate and pulse strength measurements of patients ... or battery powered unit displays a plethysmographic ... up to 30 hours of on screen ...
... is a second-generation refractive multifocal IOL that ... from glasses than monofocal IOLs. The ReZoom ... vision that monfocals cannot match. , ,The ... over five optic zones so that each ...
Medicine Products: